if you see the updated slide below, two points worth noting:
1) VP-002 is now PYC-001; which seems to indicate DR is now no longer a program/asset, and has been replaced with ADOA being the defined co-lead
2) 100% ownership for ADOA and all future Vision Pharma pipeline assets; may be a result of Lion Eye not taking up the last funding round?
For the pipeline CNS is still in the pipeline; but will likely remain undisclosed until IP is locked in
This aligns with Rohan’s presentation that 3 assets will be delivered this year, with a potential 4th as backup being worked up.
PYC, page-38
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.010(8.33%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 11.0¢ | $383.6K | 3.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 169997 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 1549 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |